United States Securities and Exchange Commission
                         Washington, D. C.  20549


                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended September 30, 2004

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

     For the transition period from                to
                                    --------------    ---------------

                       Commission File No. 000-32393
                       -----------------------------

                                eGene, Inc.
                                -----------
       (Exact Name of Small Business Issuer as Specified in its Charter)

          NEVADA                                        87-0645507
          ------                                        ----------
   (State or Other Jurisdiction of                 (I.R.S. Employer I.D. No.)
    incorporation or organization)

                   17841 Fitch, Irvine, California 92614
                   -------------------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (949) 250-8686

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the issuer was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.   Yes [X]  No [ ]


             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                              Not applicable.

Check whether the Registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.

     Yes       No
         ---     ---

                   APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the Registrant's classes
of common stock, as of the latest practicable date:

                               15,412,521

                            September 30, 2004

Transitional Small Business Disclosure Format (Check One):  Yes  X   No
                                                                ---   ---

<PAGE>

                             eGene,
                       Table of Contents
                                                       Page

PART I    FINANCIAL INFORMATION

Item 1.   Financial Statements
          Condensed Consolidated Balance Sheet as of September 30, 2004

          Condensed Consolidated Statements of Operations for the Three and
          Nine Months Ended September 30, 2004 and 2003

          Condensed Consolidated Statements of Cash Flows for the Nine Months
          Ended September  30, 2004 and 2003

          Notes to Unaudited Condensed Consolidated Financial Statements

Item 2.   Management's Discussion and Analysis of Financial Condition and
          Results of Operations

Item 3.   Controls and Procedures

PART II   OTHER INFORMATION

Item 1.   Legal Proceedings

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds

Item 3.   Defaults upon Senior Securities

Item 4.   Submission of Matters to a Vote of Security Holders

Item 5.   Other Information

Item 6.   Exhibits and Reports on Form 8-K

SIGNATURES
 EX-31.1 302 Certification of Udo Henseler
 EX-31.2 302 Certification of Jeffrey Williams
 EX-32   906 Certification

                      PART I - FINANCIAL INFORMATION

Item 1.   Financial Statements.

          The Financial Statements of the Registrant required to be filed with
this 10-QSB Quarterly Report were prepared by management, and commence on the
following page, together with Related Notes.  In the opinion of management,
the Financial Statements fairly present the financial condition of the
Registrant.
                 CONDENSED CONSOLIDATED BALANCE SHEET

                          (unaudited)
ASSETS                                              Sep 30, 04
Current Assets
     Cash                                             $813,154
     Accounts Receivable                               282,635
     Employee Advance                                    1,000
     Tooling in Progress                               219,912
     Inventory                                         140,492
                                                    ----------
Total Current Assets                                $1,457,193
Fixed Assets
     Computer Equipment                                 39,239
     Equipment and Machinery                            57,927
      Furniture and Fixtures                            18,413
     Less Accumulated Depreciation                     (66,847)
                                                    ----------
Total Fixed Assets                                      48,732
Other Assets
     Amortizable Cost, less amortization                 1,716
     Deferred Patent Costs                             246,933
     Deposits                                           24,849
                                                    ----------
Total Other Assets                                     273,498
                                                    ----------
TOTAL ASSETS                                         1,779,423
                                                    ==========
LIABILITIES AND EQUITY
     Liabilities
          Current Liabilities
               Accounts Payable                        174,023
               Accrued Payroll                          98,588
               Accrued Payroll Taxes                    10,990
               Accrued Vacation Pay                     25,057
               Advances from the Customer              100,000
                                                    ----------
          Total Current Liabilities                    408,658
     Equity
          Capital Stock                                 15,413
          Additional paid in capital                 4,644,335
          Retained Earnings                         (2,423,467)
          Net Income                                  (865,516)
                                                    ----------
     Total Equity                                    1,370,765
                                                    ----------
TOTAL LIABILITIES AND EQUITY                         1,779,423
                                                    ==========
<PAGE>
                 CONDENSED STATEMENTS OF OPERATION
                           eGene, Inc.

                                 Three Months Ended        Nine Months Ended
                                    September 30,            September 30,
                                 2004          2003      2004         2003
Revenues
     Sales                      $283,026   $  13,302   $555,489   $  13,302
     Services                                 14,220                 46,062
     Interest & Other income       2,865       1,379      4,156      10,033
                                --------   ---------   --------   ---------
Total Revenues                   285,891      28,901    559,645      69,397
                                --------   ---------   --------   ---------
Cost of Goods Sold               122,204       5,986    249,970       5,986
                                --------   ---------   --------   ---------
Gross Profit                     163,687      22,915    309,675      63,411
                                --------   ---------   --------   ---------
Expenses
     Accounting & Audit            9,800         941     19,897       8,050
     Amortization Expense            231                  1,460         922
     Bank Service Charges            150          95        723         931
     Depreciation Expense          5,329         500     33,747      13,411
     Dues and Subscriptions          279       2,348      3,493       6,415
     General Office Expenses       5,318       1,645     17,379       4,270
     Insurance                    23,083       9,911     43,542      14,199
     Legal Expenses               41,964       2,765     50,847       7,021
     Other Manufacturing &
       Production                  2,535       3,180     23,511       3,180
     Marketing & Sales            18,389      22,064     64,796      48,590
     Office Equipment              2,390                  2,642       2,071
     Office Supplies               2,065         595      4,604       5,341
     Postage and Delivery          2,830         940      5,124       2,953
     Professional Fees            52,333                 52,333
     Rent-Building                18,080       4,500     30,080      13,500
     Research & Development       82,319     113,282    328,681     238,832
     Salaries, Wages & Taxes     161,890     179,476    478,254     397,226
     Telephone & Utilities         5,117       4,792     14,078      11,930
                               ---------   ---------  ---------   ---------
Total Expenses                   434,102     347,034  1,175,191     778,842
                               ---------   ---------  ---------   ---------
Net Loss Before Income Taxes    (270,415)   (324,119)  (865,516)   (715,431)
                               ---------   ---------  ---------   ---------
Current Year provision for
Income Taxes                           0           0          0           0
                               ---------   ---------  ---------   ---------
Net Loss                        (270,415)   (324,119)  (865,516)   (715,431)
                               =========   =========  =========   =========
Loss Per Share                    ($0.02)     ($0.03)    ($0.08)     ($0.07)
                               =========   =========  =========   =========
Average Shares Outstanding    12,833,305  10,728,683 11,197,406  10,728,683
                              ----------  ---------- ----------  ----------
<PAGE>
            CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (unaudited)

                                 Three Months Ended        Nine Months Ended
                                    September 30,            September 30,
                                 2004          2003      2004         2003
Cash Flows From Operating Activities
  Net Income (Loss)               (270,415)  (324,119)    (865,516)  (715,431)
  Adjustments to net income
  (loss) to net cash provided by
  operations:
     Amortization                      231                   1,460        922
     Depreciation                    5,329        500       33,747     13,713
     (Increase) decrease in
      current assets              (388,749)  (163,658)    (452,372)  (177,151)
     (Increase) decrease in
      other assets                 (29,546)   (70,329)     (60,766)   (97,793)
     Increase (decrease) in
      current liabilities         (189,369)   212,683       40,401    252,132
                               -----------  ---------   ----------  ---------
Net cash provided (used) by
operating activities              (872,519)  (344,923)  (1,303,046)  (723,608)
                               -----------  ---------   ----------  ---------

Cash Flows from Investing Activities
  Purchase of furniture,
  fixtures and equipment                 -          -      (19,191)         -
                               -----------  ---------   ----------  ---------
Net cash used in investing
activities                               -          -      (19,191)         -

Cash Flows from financing
  Capital stock issued           1,521,956    300,000    1,860,199    914,303
                               -----------  ---------   ----------  ---------
Net Increase (Decrease) in cash    649,437    (44,923)     537,962    190,695

Cash at beginning of period        163,717    466,038      275,192    230,420
                               -----------  ---------   ----------  ---------
Cash at end of period              813,154    421,115      813,154    421,115
                               ===========  =========   ==========  =========
Supplemental disclosure of cash flow information:
  Interest paid                          0          0            0          0
  Income taxes paid                      0          0          800          0
Items not affecting cash                 0          0            0          0

                     See accompanying notes.
<PAGE>
                           eGene, Inc.
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                        September 30, 2004
                           (Unaudited)

1. ORGANIZATION AND INTERIM FINANCIAL STATEMENTS

     Effective July 13, 2004, Centroid Consolidated Mines Co., (Centroid)
completed a merger with BioCal Technology, Inc., (BioCal) a California
corporation in the business of developing, manufacturing, and marketing
analytical systems and reagents for the global genotyping market.

     The merger caused BioCal to become a wholly-owned subsidiary of Centroid,
a dormant, publicly held Nevada corporation.  The terms of the merger provide
that Centroid exchange one of its shares of common stock for every three
outstanding shares of common stock of BioCal and one of its options to acquire
shares of common stock of Centroid for every three outstanding options to
acquire common stock of BioCal, with the option exercise price of the BioCal
options to be adjusted times three as a result of the exchange.  The
combination is a "reverse merge" which essentially results in the owners of
BioCal controlling the post-merger entity.  They became owners of
approximately 73% of the reorganized company.  The transaction is accounted
for as a recapitalization of BioCal wherein the net assets are brought forward
at their net book value with no goodwill recognized, and the pre-merger
financial statements of BioCal are now the historical financial statements of
the combined company.

     The directors and executive officers of BioCal became the directors and
officers of the reorganized entity which also has changed its name to eGene,
Inc.

     The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-QSB and
Article 10 of Regulation S-X of the Securities and Exchange Commission
("SEC").  Accordingly, they do not include all of the information and
footnotes required by accounting principles generally accepted in the United
States for complete financial statements.   In the opinion of management, all
adjustments (consisting of normal recurring entries) considered necessary for
a fair presentation have been included.  Operating results for the three and
nine months ended September 30, 2004, are not necessarily indicative of the
results that may be expected for the year ending December 31, 2004.

Principles of Consolidation

     eGene's financial statements include the accounts of its wholly owned
subsidiary BioCal Technology, Inc, All significant inter-company balances and
transactions have been eliminated in consolidation.

Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations

     This Management's Discussion and Analysis of Financial Condition and
Results of Operations as of September  30, 2004, and for the three and nine
month periods ended September 30, 2004, and September 30, 2003, should be read
in conjunction with our financial statements included in the 8-K Current
Report dated July 15, 2004, and our Management's Discussion and Analysis of
Financial Condition and Results of Operations included therein that was filed
with the Securities and Exchange Commission on September 2, 2004.

     Statements made in this Form 10QSB Quarterly Report which are not purely
historical are forward-looking statements with respect to our goals, plan
objectives, intentions, expectations, financial condition, results of
operations, future performance and business, including, without limitation,
(i) our ability to raise capital, and (ii) statements preceded by, followed by
or that include the words "may," "would," "could," "should," "expects,"
"projects," "anticipates," "believes," "estimates," "plans," "intends,"
"targets" or similar expressions.  Forward-looking statements involve inherent
risks and uncertainties, and important factors (many of which are beyond our
Company's control) that could cause actual results to differ materially from
those set forth in the forward-looking statements, including the following,
general economic or industry conditions, nationally and/or in the communities
in which we conduct business, changes in the interest rate environment,
legislation or regulatory requirements, conditions of the securities markets,
our ability to raise capital, changes in accounting principles, policies or
guidelines, financial or political instability, acts of war or terrorism,
other economic, competitive, governmental, regulatory and technical factors
affecting our operations, products, services and prices.

     Accordingly, results actually achieved may differ materially from
expected results in these statements.  Forward-looking statements speak only
as of the date they are made.  We do not undertake, and specifically
disclaims, any obligation to update any forward-looking statements to reflect
events or circumstances occurring after the date of such statements.

Executive Summary.
------------------

Business.
---------

     We are an emerging biotechnology company that utilizes our low cost
core technologies of capillary electrophoresis, microfluidics, advanced
reagent and liquid handling and automation to create leading edge and novel
genotyping DNA fragment testing tools for the biological/microbial materials
and life sciences testing industries.  Our strategy is to deliver applications
and tools to these industries that we believe will have immediate commercial
relevance.  Our genotyping DNA HDA-GT12 system detects, quantifies, identifies
and characterizes biological organisms.  It automates routine and non-routine
laboratory and industrial procedures for the introduction of new production,
product development, quality control, safety methods and productivity.

     While there are many applications critical to biological materials'
management for our technology platform, like the food, beverages,
environmental, sanitation, hygiene, pharmaceutical manufacturing, veterinary,
military bio-defense and research and development labs industries, among
others, we are currently addressing the relevant genotyping testing
applications in the major market segments of research, development and genetic
testing labs; medical schools; research hospitals; and food.

     Our management believes that our products and technologies are uniquely
capable of addressing these markets.  Customers need information which will
give them unprecedented confidence in the quality of their products as to
microbial and biological materials testing information, and we believe
that we have addressed an urgent and increased industry need for a reliable,
accurate, deskilled, high-throughput, low cost genotyping tool for DNA
fragment experimentation and testing.

     We are developing three channels of distribution for our products:
direct to customers, indirect through our international network of
distributors, and through our, at this stage, early and developing original
equipment manufacturer ("OEM") channels.  Through these distributor channels,
we sell complete systems solutions, developed by us, to end customers.  Our
OEM distribution channel is only at its very early development stage, but
is an example, and is complementary to its distribution network activities as
it enables us to extend the commercial potential of our capillary microfluidic
genotyping DNA HDA-GT12 system and advanced reagent and liquid handling
technologies into new industries and new applications with experienced
commercial partners. In the OEM channel, we plan to provide our enabling
technologies to potential commercial partners who then typically integrate the
application solution and market them to their end customers.

     By using direct, indirect distribution, and eventually OEM channels to
maximize penetration of our products and technologies into the marketplace,
we seek to position our Company as a leader in the low cost genomics tools
testing market.

     For additional information, please visit our web side at
www.eGene.com.

Third Quarter Overview.
-----------------------

     During the third quarter of 2004, we achieved several significant
financial milestones. As reflected in our CONSOLIDATED STATEMENTS OF
OPERATIONS contained in our Consolidated Financials Statements in Part I, Item
1 of this Quarterly Report, our sales increased $270,000, or 928% from sales
of $28,000 in the third  quarter of 2003.  This increase in our quarterly
sales reflects our continued early product sales ramp up in our acquisition of
BioCal Technology, Inc. ("BioCal Technology") in July of 2004.  Sales during
the nine months ended September 30, 2004, were $555,000 as compared to $59,000
in the same period during 2003.  We believe that the increases in sales boosts
our confidence to achieve more appreciable growth in the future.  We expect
our higher future sales to result in reduced operating losses and improved
operating cash flows.

     Our continuing goal is to attain sustainable revenue growth through
increased sales of our instruments to a more diversified and global customer
base and by increasing the percentage of our total sales that arises from
recurring sales sources such as consumable or aftermarket products.

     In addition to our goal of attaining more sustainable sales growth, we
are continuing to focus on improving our gross margins and controlling product
costs by seeking out the benefits of cost effective global low cost sourcing
in order to achieve operating cash flow break-even at lower overall sales.

     eGene Inc. (EGEI.OB), resulted from of a completed merger, effective in
the State of California on July 14, 2004, between Centroid Consolidated Mines
Co., which is our publicly-held company, and BioCal Technology, which was a
privately-held entity.  The two companies adjusted outstanding shares, options
and warrants on a 1:3 basis.  Intellectual properties, technologies and
personnel resources were then combined to create a leading-edge biotechnology
company with ready products believed to have immediate commercial relevance.
In conjunction with this merger, we raised $1.6 million in private funding.
We, previously known as "Centroid Consolidated Mines Co.", had no material
business operations at the time that we acquired BioCal Technology.

     We believe that we are on target to achieve our objective of achieving
positive cash flows from operating activities by the fourth quarter of 2005.

     During 2004, we enhanced our product position with introductions of new
product applications and two new Gel Cartridges (4 and 8 channels) with
integrated gel-chemistries designed to handle different samples capacities
with high detection sensitivity and reproducibility to enhance user
productivity.

     Over the next several quarters, we intend to introduce new high value
application targets.  While we are unable to project future sales from these
new introduction, we believe that the expanded ability to perform new and
high confidence analyses, will greatly enhance our  positioning by
allowing scientists to conduct industrial microbiological analyses that were
previously not well or not at all accomplished with the traditional testing
technology platforms.

     We also continue to aggressively pursue our genotyping microfluidics
adoption strategy and promote our enhanced product position to our expanding
customer base.  Examples of these activities were/are our distributor and
customer training tutorials during which we present our newest solutions to
existing and prospective customers.  A number of these programs have generated
new sales and leads that we believe will result in incremental product sales
for the first half of 2005.

Critical Accounting Policies.
-----------------------------

     Certain accounting policies used in the preparation of our financial
statements in this report are described in our Management's Discussion and
Analysis of Financial Condition and Results of Operations.

Results of Operations.
----------------------

Revenue.
--------

     Total sales increased for the three and nine months ended September 30,
2004, as compared to the same periods in 2003.  Our sales increased $256,000,
or 928% from sales of $28,000 in the third quarter of 2003.  Sales during the
nine months ended September 30, 2004, were $555,000 as compared to $59,000 in
the same period during 2003.  This increase in our quarterly and the nine
months sales reflect our continued early product sales ramp up in our
acquisition of the young private BioCal Technology in July of 2004.  The
increases in sales boost our confidence to achieve more appreciable growth in
the future.  We expect our higher future sales to result in reduced operating
losses and improved operating cash flows.  We had no material business
operations at the time that we acquired BioCal Technology.

                   Three Months Ended              Nine Months Ended
                     September 30,                    September 30,
               2004     2003   $change %change  2004     2003   $change%change
Product Sales $283,026 $27,522 $255,504  928% $555,489  $59,364 $496,125  836%
Cost of Sales  122,204   5,986  116,218 1942%  249,970    5,986  243,984 4076%
Total Expenses 434,102 347,034   87,068   25%1,175,191  778,842  396,349   51%
Net Loss      (270,415)(324,119) 53,704  -17% (865,516)(715,431)(150,085)  21%

Cost of Sales.
--------------

     In addition to our goal of attaining more sustainable revenue growth, we
are continuing to focus on improving our gross margins and controlling product
costs by seeking out the benefits of cost effective global low costs sourcing
opportunities in order to achieve operating cash flow break-even at lower
overall revenues.

Expenses.
----------

     Total expenses for the quarter ended September 30, 2004, were $434,000
and $87,000 higher as compared to the same periods in 2003.  Total expenses
for the nine months ended September 30, 2004, were $1,175,191 and $396,349
higher compared to the same periods in 2003.

     The major expenses levels and increases were for payroll and research and
development materials.  The level of ongoing research and development expense
is highly dependent upon the number and significance of ongoing projects at
any particular time.  We currently expect research and development expenses to
continue to increase in future periods as we develop new product solutions and
enhancements.  We expect research and development spending to increase, but
only expanding in subsequent years based upon customer demand, market
conditions and our commercial growth.  Management expects to devote additional
expenses resources to continue our research and development efforts, to expand
support and product development activities and for other general corporate
activities.

     Selling, general and administrative expenses are expected to increase
primarily due to planned increased sales calling  for increases in employment
costs related to our first putting in place marketing, sales and service
functions, and general increases in other marketing and general and
administrative expenses as a result of expected increased  commercial
activities.  We expect selling, marketing and product promotion expenses to
grow over the next several years to support the more global commercialization
of our products.  Certain General and Administrative expenses in the legal and
insurance categories increased primarily due to merger related activities.
We anticipates that general and administrative expenses will continue to
increase but at a lesser percentage rate of sales.

     The net loss for the quarter ended September 30, 2004, was $270,000
compared to the previous year quarter loss of $324,000.

     Interest income, net increased due to higher cash, cash equivalents and
marketable securities balances over the three months ended September 30, 2004,
as compared to the same periods in 2003.

     Interest income, net decreased due to lower cash, cash equivalents and
marketable securities balances the nine months ended September 30, 2004, as
compared to the same periods in 2003 and declines in interest rate yields over
the comparable periods.

Liquidity and Capital Resources.
--------------------------------

     Our cash and cash equivalents were $813,000 at September 30, 2004,
compared to $275,000 at of December 31, 2003.

     We have financed our operations from inception primarily through equity
sales and initial product sales and services.  The inclusion of BioCal
Technology's results of operations after July 14, 2004, had a significant
impact on the business and the comparability of cash flows on a
period-over-period basis.

Cash Flows.
-----------

                             Nine Months Ended September 30,
                                                     Increase/
Cash provided by (used in)        2004       2003    (decrease)
Operating activities          (1,303,046)  (723,608)  (579,438)
Investing activities             (19,191)              (19,191)
Financing activities           1,860,199    914,303    945,896

Operating Activities.
---------------------

     During the nine months ended September 30, 2004, we used $1.3 million of
cash for operating activities as compared to $0.7 million of cash used in the
same period of 2003.  Current assets - receivables, inventory and other
current assets nominally offset by increases in current liabilities - used
cash of $0.5 million, and operations used $0.8 million during the nine months
ended September 30, 2004.  The increased use of cash for accounts receivable
was due to increases of our product sales  base.  The increase in use of cash
for inventories during the nine months ended September 30, 2004, is primarily
related to an increase in inventory levels related to expected increases in
future product sales. In 2003, including  our acquisition of BioCal
Technology, we had low inventories as product sales were not significant.

Investing Activities.
---------------------

     Investing activities during the nine months ended September 30, 2004,
were $19,000 for additional furniture, fixture and equipment purchases.

Financing Activities.
---------------------

     During the nine months ended September 30, 2004, we generated $1.9
million in cash from financing activities, reflecting the sale of our common
stock in various private placements and options exercises.

     We believe that our current cash balances and our expected successful
current in process private placement of "restricted securities" to "accredited
investors" only, together with the revenue to be derived from our commercial
sales from our genotyping products will be sufficient to fund our operations
at least through the early part year 2005.  Our future capital requirements
will depend on many factors, including, among others:

     * continued market acceptance of our genotyping  products;

     * continued scientific progress in product development programs;

     * the magnitude and scope of our research and product development
       programs;

     * its ability to maintain and establish additional, partnerships and
       licensing arrangements;

     * the time and costs involved in expanding and maintaining our
       manufacturing facilities;

     * the costs involved in preparing, filing, prosecuting, maintaining,
       defending and enforcing patent claims;

     * the potential need to develop, acquire or license new technologies and
       products; and

     * other factors not within our control.

    We expect to attain positive cash flows from operations by the fourth
quarter of 2005, and we believe that current and expected cash balances are
adequate to satisfy cash needs at least through the early part of 2005.  Our
actual cash needs could vary considerably, however, depending on opportunities
and commercial uncertainties that may arise over the course of the remaining
period of  2004 and the full year 2005.  During or after this period, if
cash generated by operations is insufficient to satisfy our liquidity
requirements, we may need to sell additional equity or debt securities or
obtain additional credit arrangements.  An inability to obtain additional
financing may force delays in research and product development activities and,
ultimately, cause us to cease operations.

    We have incurred operating losses since our inception and expects to
incur losses for the foreseeable future.  We will continue to make investments
in research and development and infrastructure building over the next several
years.

RISK FACTORS AFFECTING OPERATING RESULTS.
-----------------------------------------

     The following risk factors should be considered, among others, in
evaluating eGene 's business, products and prospects.  This list is not
inclusive.

Risks Related To Its Business.

     The Genotyping Products May Not Achieve Market Acceptance, Which Could
Cause Revenue to Grow Slowly or Decline.
----------------------------------------

     Our genotyping products, which were developed prior to our merger on
July 14, 2004, with and by BioCal Technology , have only recently begun to be
used commercially.  If these systems do not gain further market acceptance,
we will be unable to generate significant sales of these products and its
revenue may grow more slowly than expected or decline.  The commercial success
of our genotyping products will depend upon capital spending by our potential
customers, and market acceptance of the merits of our genotyping capillary
electrophoresis systems by biotechnology companies, academic research centers
and other companies that rely upon genotyping analyses.  Market acceptance
will depend on many factors, including:

     * Our ability to demonstrate the advantages and potential economic value
of our genotyping systems over alternative well-established technologies;

     * capital spending by our customers and potential customers, which has
been sluggish as a result of current economic conditions and other industry-
specific factors; and

     * our ability to market our genotyping systems.

     Because the genotyping capillary electrophoresis systems have been in
operation for only a limited period of time, their accuracy, reliability, ease
of use and commercial value have not been fully established.  If the early
customers do not endorse our genotyping systems because these systems fail
to generate the quantities and quality of data they expect, are too difficult
or costly to use or are otherwise deficient, market acceptance would suffer
and further sales may be limited.  We cannot assure you that these customers'
efforts to put our high throughput systems into use will continue or will be
expeditious or effective.  Potential customers for these systems may also wait
for indications from our early genotyping system customers that our system
works effectively and generates substantial benefits.  Further, non-acceptance
by the market of our initial systems could undermine not only those systems
but subsequent systems as well.

     The genotyping productivity tools equipment market is competitive and is
characterized by technological change and frequent new product introductions.
The commercial success of company genotyping systems depends upon continued
and expanding market acceptance of our systems and products by biotechnology
companies and genomics research organizations, and upon availability to
address quickly any performance problems that our customers encounter.  We
anticipates that our competitors will introduce new, enhanced products in this
market.  Our future success will depend on our ability to offer new products
and technologies that researchers believe are an attractive alternative to
current products and technologies that address the evolving needs of our
customers and that are technologically superior to new products that may be
offered by competitors.  We may experience difficulties or delays in the
development efforts for new products, and we may not ultimately be successful
in developing them.  Any significant delay in releasing new products in this
market could adversely affect our reputation, give a competitor a
first-to-market advantage or cause a competitor to achieve greater market
share.

     We intend to continue developing new, lower cost versions of our
genotyping systems with enhanced features that address existing or emerging
customer needs, such as novel assay functionalities.  If we are unable to do
so, our systems may not become more widely used and we may experience a
decline in revenue or slow revenue growth and may not achieve or maintain
profitability.

     eGene's Business May Be Adversely Affected by Downturns in the Economy.
     -----------------------------------------------------------------------

     We are subject to the capital spending patterns of this industry, which
over the past several years have been unfavorably impacted by general economic
conditions and increased competition.  If our customers and potential
customers do not increase their capital spending budgets, we could face weak
demand for our products.

     eGene's Industry Is Very Competitive.
     -------------------------------------

     Our business is highly competitive and our growth is dependent upon
market growth and our ability to enhance our existing products and introduce
new products on a timely basis.  One of the ways we may address the need to
develop new products is through acquisitions of complementary businesses and
technologies.  Acquisitions involve numerous risks.

     eGene Has Not Recorded Profitable Operations since its Inception and May
Never Achieve Profitably.
-------------------------

     We expect to incur future operating losses and may not achieve
profitably.  We have experienced development stage operating losses each year
since our inception and expect to incur additional operating losses for the
calendar year of 2004, primarily as a result of a current slow economic
climate, and expected continuing expenses for manufacturing capabilities,
research and product development costs and general and administrative costs.
We may never achieve profitability.

     Our operating results may fluctuate significantly and any failure to meet
financial expectations may disappoint securities analysts or investors and
result in a decline in our stock price.

     eGene Has Limited Manufacturing Experience.
     -------------------------------------------

     We have limited experience in manufacturing of our products and may
encounter manufacturing problems or delays, which could result in lost
revenue.

     eGene Depends on its Key Personnel, the Loss of Whom Would Impair its
Ability to Compete.
--------------------

     We are highly dependent on the principal members of our management (CEO
 Dr. Udo Henseler, Dr. Ming Liu and Varouj Amirkhanian  - world-class
scientists).  The loss of services of any of these persons could seriously
harm product development and commercialization efforts.  In addition,
research, product development and commercialization will require additional
skilled personnel in areas such as chemistry and biology, software engineering
and electronic engineering.  Competition for and retention of personnel,
particularly for employees with technical expertise, is intense and the
turnover rate for these people is high.  If we are unable to hire, train and
retain a sufficient number of qualified employees, our ability to conduct and
expand our business could be reduced.  The inability to retain and hire
qualified personnel could also hinder the planned expansion of its business.

     eGene's Intellectual Property Rights May Not Protect it and its Products.
     -------------------------------------------------------------------------

     Our product could infringe on the intellectual property rights of
others, which may cause us to engage in costly litigation and, if we are not
successful, could also cause us to pay substantial damages and prohibit us
from selling our products.  Third parties may assert infringement or other
intellectual property claims against us.  Even if these claims are without
merit, defending a lawsuit takes significant time, may be expensive and may
divert management attention from other business concerns.  We are not aware
of any third-party patents claims against us.

     We may need to initiate lawsuits to protect or enforce our patents,
which would be expensive and, if we lose, may cause us to lose some of our
intellectual property rights, which would reduce our ability to compete in the
market.  We rely on patents to protect our intellectual property and our
competitive position, especially in our capillary electrophoresis
microfluidics business.  The rights we relies upon to protect our intellectual
property underlying company products may not be adequate, which could enable
third parties to use this technology and would reduce our ability to compete
in the market.

     In addition to patents, we rely on a combination of trade secrets,
copyright and trademark laws, nondisclosure agreements and other contractual
provisions and technical measures to protect our intellectual property rights.
Nevertheless, these measures may not be adequate to safeguard the technology
underlying company products.

     Notwithstanding our efforts to protect our intellectual property, our
competitors may independently develop similar or alternative technologies or
products that are equal or superior to company technology and products without
infringing on any of our intellectual property rights or design around company
proprietary technologies.

     The Loss of One or More Suppliers of eGene May Have an Adverse Effect on
its Operations.
---------------

     We obtain some of the components and subassemblies included in our
systems from a single source or a limited group of suppliers, and the partial
or complete loss of one of these suppliers could cause production delays and a
substantial loss of revenue.

     We maintain only a limited number of long-term supply agreements with
its suppliers.

     Our reliance on a limited group of suppliers involves several risks,
including the following:

     * we may be unable to obtain an adequate supply of required components;

     * we have reduced control over pricing and the timely delivery of
components and subassemblies; and

     * company suppliers may be unable to develop technologically advanced
products to support our growth and development of new systems.

     Because the manufacturing of certain of these components and
subassemblies involves complex processes and requires long lead times, we
may experience delays or shortages caused by suppliers.  We believe that
alternative sources could be obtained at the same prices and on substantially
the same terms and conditions, if necessary, for most sole and limited source
parts.  However, if we were forced to seek alternative sources of supply or to
manufacture such components or subassemblies internally, we might be forced to
redesign company systems, which could prevent us from shipping our systems to
customers on a timely basis.

     eGene May Need Additional Capital.
     ----------------------------------

     Failure to raise additional capital or generate the significant capital
necessary to expand eGene's operations and invest in new products could reduce
our ability to compete and result in lower revenue.  We anticipate that
our existing capital resources and in progress private placements will
enable us to maintain currently planned operations at least through the early
year 2005.  However, we premises this expectation on our current operating
plan, which may change as a result of many factors.  Consequently, we may need
additional funding sooner than anticipated.  Our inability to raise needed
capital would harm our business. In addition, we may choose to raise
additional capital due to market conditions or strategic considerations even
if we believe we have sufficient funds for our current operating plans.  To
the extent that additional capital is raised through the sale of equity or
convertible debt securities, the issuance of these securities could result in
dilution to company stockholders.

     We currently has no credit facility or committed sources of capital.
To the extent operating and capital resources are insufficient to meet future
requirements; we will have to raise additional funds to continue the
development and commercialization of our technologies.  These funds may not be
available on favorable terms, or at all.  If adequate funds are not available
on attractive terms, we may be required to curtail operations significantly or
to obtain funds by entering into financing, supply or collaboration agreements
on unattractive terms

Risks Related to Owning Our Common Stock .
------------------------------------------

     Our stock price has very little history and you could lose a substantial
portion of your investment.

     Our stock has been trading on the Bulletin Board only since October 2004.
We initially offered our common stock to the public at $1.00 per share. We
expect that our stock price will remain volatile as a result of a number of
factors, including:

      *   announcements by our competitors of complementary or competing
          products and technologies;

      *   announcements of our financial results, particularly if they
          differ from investors' expectations; and

      *   general market volatility for technology stocks.

     These factors and fluctuations, as well as general economic, political
and market conditions, may materially adversely affect the market price of our
common stock.

     We are at risk of future securities class action litigation.

     Given the newness of our stock, we are at risk of having securities class
action lawsuits filed against us and our officers and directors.  Such
securities litigation could result in potential liability, cause us to incur
litigation costs and divert management's attention and resources, any of which
could harm our business.  In addition, announcements of lawsuits of this or
some other nature, and announcements of events occurring during the course of
the lawsuits, could cause our stock price to drop.

Item 3. Controls and Procedures

     We evaluated our "disclosure controls and procedures" and our "internal
controls and procedures for financial reporting" as of September 30, 2004.
This evaluation was done under the supervision and with the participation of
management, including our chief executive officer and our principal financial
officer.

Evaluation of disclosure controls and procedures.
-------------------------------------------------

     Disclosure controls are procedures that are designed with the objective
of ensuring that information required to be disclosed in our reports filed
under the Securities Exchange Act of 1934, such as this Quarterly Report on
Form 10-Q, is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission's ("SEC") rules
and forms. Disclosure controls are also designed with the objective of
ensuring that such information is accumulated and communicated to our
management, including the chief executive officer and principal financial
officer, as appropriate to allow timely decisions regarding required
disclosure.

     Subject to the limitations set forth below, based on their evaluation, as
of the end of this reporting period, the chief executive officer, Executive
Vice Presidents  and the principal financial officer have concluded that our
disclosure controls and procedures are effective to ensure that information we
are required to disclose in reports that we file or submit under the
Securities Exchange Act of 1934 is recorded, processed, summarized, and
reported within the time periods specified in SEC rules and forms.

Changes in internal controls.
-----------------------------

     Internal controls over financial reporting are procedures which are
designed with the objective of providing reasonable assurance that: (1) our
transactions are properly authorized; (2) our assets are safeguarded against
unauthorized or improper use; and (3) our transactions are properly recorded
and reported, all to permit the preparation of our financial statements in
conformity with accounting principles generally accepted in the United States.
Among other matters, we evaluated our internal controls over financial
reporting to determine whether there were any "significant deficiencies" or
"material weaknesses," and sought to determine whether we have identified
any acts of fraud involving personnel who have a significant role in eGene's
internal controls. In the professional auditing literature, "significant
deficiencies" may be interpreted as being comparable as "reportable
conditions"; these are control issues that could have a significant adverse
effect on the ability to record, process, summarize, and report financial data
in the financial statements.  A "material weakness" is defined in the auditing
literature as a particularly serious reportable condition where the internal
control does not reduce to a relatively low level the risk that misstatements
caused by error or fraud may occur in amounts that would be material in
relation to the financial statements and would not be detected within a timely
period by employees in the normal course of performing their assigned
functions.

     There were no material changes in our internal controls over financial
reporting during the quarter ended September 30, 2004, that have materially
affected, or are reasonably likely to materially affect, our internal control
over financial reporting.

     Consistent with Section 10A(i)(2) of the Securities Exchange Act of 1934,
as added by Section 202 of the Sarbanes-Oxley Act of 2003, we are responsible
for listing the non-audit services approved by our Chief Executive Officer
to be performed by Mantyla McReynolds LLC, our independent auditor.  Non-
audit services are defined as services other than those provided in connection
with an audit or a review of our financial statements.

Limitations on the Effectiveness of Controls.
---------------------------------------------

     Our management, including our chief executive and principal financial
officer, does not expect that our disclosure controls or our internal controls
will prevent all error and all fraud.  A control system can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints, and the benefits of controls must be
considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of controls can provide absolute assurance that
all control issues and instances of fraud, if any, within eGene have been
detected.  These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of simple
error or mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people or by management
override of the control.  Because of the inherent limitations in a cost-
effective control system, misstatements due to error or fraud may occur and
not be detected.

                   Part II   Other Information

Item 1. Legal Proceedings

     None; not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     10,137,052 shares of common stock and 821,975 options to purchase common
stock under the merger with BioCal Technology effective on July 14, 2004.  See
the 8-K Current Report of our Company dated July 14, 2004, that was filed with
the Securities and Exchange Commission on September 2, 2004, and is
incorporated herein by reference.

Item 3. Defaults Upon Senior Securities

     None; not applicable.

Item 4. Submission of Matters to a Vote of Security Holders

     None; not applicable.

Item 5. Other Information

     eGene's Board of Directors  pre-approves all audit and permissible non-
audit services provided by its independent auditors.  For 2004, the Board of
Directors  has pre-approved $5,000 for tax compliance and consulting
services provided by its independent auditors.

Item 6.   Exhibits and Reports on Form 8-K

a.   Exhibits

     31.1 302 Certification of Udo Henseler

     31.2 302 Certification of Jeffrey Williams

     32   906 Certification

b.   Reports on Form 8-K

      8-K Current Report dated July 14, 2004 filed with the Securities and
Exchange Commission on July 14, 2004.

      8-K Current Report dated July 15, 2004 filed with the Securities and
Exchange Commission on September 2, 2004.

                          SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                   eGene, Inc.



Dated: November 12, 2004           By:    /s/ Udo Henseler
                                   Udo Henseler
                                   Chairman of the Board and Chief
                                   Executive Officer


Dated: November 14, 2004           By:    /s/ Jeffrey Williams
                                   Jeffrey Williams
                                   Chief Financial Officer

<PAGE>